Jay Edelberg
Co-founder & Chief Medical OfficerDr. Jay Edelberg, M.D., Ph.D, has been Secretary & Executive Director at Prolaio, Inc. Dr. Edelberg co-founded Prolaio, Inc. in December 2021 and served as its Head of Research and Development.and a member of its board of directors prior to our acquisition of Prolaio, Inc. in February 2025. He is a Co-founder at Kardigan, Inc and serves as its Chief Medical Officer since August 2023. He was Senior Vice President of Clinical Development of MyoKardia, Inc. Dr. Edelberg led cardiovascular drug development at Sanofi, where he spearheaded the development of Praluent® and oversaw the clinical development and global project teams involved in the MyoKardia partnership. Previously, Dr. Edelberg directed cardiovascular biomarker research at Bristol-Myers Squibb, where he served as the U.S. medical lead for Eliquis® and at Glaxo SmithKline. Prior to his time in industry, he served as an Associate Professor of Medicine (Cardiology) at Weill Medical College of Cornell University. He trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology).He served as Senior Vice President of Global Drug Development at Bristol Myers Squibb from November 2020 to October 2021. He holds a B.S Degree in Bioengineering from Columbia University and an M.D. and Ph.D. from Duke University.
Positions
- Company NameKardigan, Inc.Stock CodeKARDPositionCo-founder & Chief Medical OfficerColleagues
- TATassos Anastasios E. GianakakosCo-Founder, President, CEO & Chairman
- BPBrianne PuglisiChief Financial Officer
- BMBob McDowellCo-founder & Scientific Advisor
- LALeslie A. LeinwandCo-Founder
- KJKimberly Johnston PopovitsIndependent Director
- DPDavid P. MeekerIndependent Director
- KRKristin ReinkeIndependent Director
- PLPaul L. BernsIndependent Director
